Literature DB >> 15800680

Immunohistochemical analysis of c-myc, c-jun and estrogen receptor in normal, hyperplastic and neoplastic endometrium.

Sema Bircan1, Arzu Ensari, Sibel Ozturk, Nural Erdogan, Ilkkan Dundar, Firat Ortac.   

Abstract

To evaluate the role of c-jun and c-myc proto-oncogenes in normal, hyperplastic and neoplastic endometrium in relation to estrogen receptor (ER) status and to investigate whether these genes can be related to other histopathological features of endometrial carcinoma, 32 endometrial carcinomas, 38 endometrial hyperplasias and 22 cyclic endometria (10 proliferative and 12 secretory) were evaluated histologically. Endometrial hyperplasia cases were classified as simple and complex hyperplasia without atypia, and atypical hyperplasia. Endometrial carcinoma cases were subtyped according to the International Society of Gynecological Pathologists. Modified FIGO system was used for both grading and staging. Immunohistochemical examination was performed using antibodies to ER-alpha, c-myc and c-jun with streptavidin-biotin-peroxidase technique. The mean percentage of ER-alpha positive cells changed cyclically during the menstrual cycle, and it was the highest (96%) and the lowest (31.6%) in proliferative and carcinomatous endometrium, respectively. There was a statistically significant difference between proliferative and secretory phases and proliferative and carcinomatous endometrium in relation to ER-alpha staining (p<0.05). There was also a statistically significant difference with respect to ERalpha reactivity between secretory phase and each hyperplastic group, as well as between the carcinoma group and each hyperplastic group (p<0.05). Although not significant, the mean percentage of c-myc expressing cells in the carcinoma group was higher (15.3%) than that of proliferative phase and hyperplastic groups. The mean percentage of c-jun positive cells in proliferative endometrium was slightly higher than in secretory endometrium, and it was the highest in atypical hyperplastic endometrium (28.3%), but there was no statistically significant difference between the groups. In carcinoma cases, a positive correlation was observed between c-jun positivity and tumor grade (p=0.027, r=0.3908), but such a correlation with c-myc was not found. A positive correlation was detected between ER-alpha and c-myc expression (p=0.038, r=0.3686). A progressive loss of ER seems to be correlated with increasing malignant transformation. C-myc expression might play a role in the development of endometrial carcinoma via ER. The association between c-jun and ER appears to be lost in endometrial carcinoma. The relationship between c-myc, c-jun and ER appears to be altered in endometrial carcinoma compared to that of menstrual endometrium.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15800680     DOI: 10.1007/BF03032403

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  46 in total

1.  The oestrogen receptor (ER) in normal and abnormal uterine tissue.

Authors:  K J Neis; P Brandner; K Ulrich-Winkelspecht
Journal:  Eur J Cancer       Date:  2000-09       Impact factor: 9.162

2.  c-myc protooncogene polypeptide expression in endometriosis.

Authors:  R S Schenken; J V Johnson; R M Riehl
Journal:  Am J Obstet Gynecol       Date:  1991-04       Impact factor: 8.661

3.  Oncogene alterations in endometrial carcinoma.

Authors:  M P Borst; V V Baker; D Dixon; K D Hatch; H M Shingleton; D M Miller
Journal:  Gynecol Oncol       Date:  1990-09       Impact factor: 5.482

4.  Tissue differences in the expression of mRNAs of Ha-ras, c-myc, fos and jun in human uterine endometrium, myometrium and leiomyoma under the influence of estrogen/progesterone.

Authors:  J Fujimoto; M Hori; S Ichigo; M Nishigaki; T Tamaya
Journal:  Tumour Biol       Date:  1994

5.  Temporal and cell-type specific expression of c-fos and c-jun protooncogenes in the mouse uterus after estrogen stimulation.

Authors:  S Yamashita; A Takayanagi; N Shimizu
Journal:  Endocrinology       Date:  1996-12       Impact factor: 4.736

6.  DNA ploidy, cell proliferation and steroid hormone receptors in endometrial hyperplasia and early adenocarcinoma.

Authors:  R Punnonen; J Mattila; T Kuoppala; T Koivula
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

7.  Cell type-specific localization of c-myc protein in the mouse uterus: modulation by steroid hormones and analysis of the periimplantation period.

Authors:  Y M Huet-Hudson; G K Andrews; S K Dey
Journal:  Endocrinology       Date:  1989-09       Impact factor: 4.736

8.  Estrogen-induced proliferation of normal endometrial glandular cells is initiated by transcriptional activation of cyclin D1 via binding of c-Jun to an AP-1 sequence.

Authors:  Tanri Shiozawa; Tsutomu Miyamoto; Hiroyasu Kashima; Kohzo Nakayama; Toshio Nikaido; Ikuo Konishi
Journal:  Oncogene       Date:  2004-11-11       Impact factor: 9.867

9.  Expression of steroid receptor coactivators and corepressors in human endometrial hyperplasia and carcinoma with relevance to steroid receptors and Ki-67 expression.

Authors:  Junko Uchikawa; Tanri Shiozawa; Hsien-Chang Shih; Tsutomu Miyamoto; Yu-Zhen Feng; Hiroyasu Kashima; Kenji Oka; Ikuo Konishi
Journal:  Cancer       Date:  2003-11-15       Impact factor: 6.860

10.  Differentially regulated immediate early genes in the rat uterus.

Authors:  R M Bigsby; A Li
Journal:  Endocrinology       Date:  1994-04       Impact factor: 4.736

View more
  11 in total

1.  Uterine microRNA signature and consequence of their dysregulation in uterine disorders.

Authors:  Nasser Chegini
Journal:  Anim Reprod       Date:  2010-07       Impact factor: 1.807

Review 2.  MicroRNA signature and regulatory functions in the endometrium during normal and disease states.

Authors:  Qun Pan; Nasser Chegini
Journal:  Semin Reprod Med       Date:  2008-10-24       Impact factor: 1.303

3.  Autocrine human growth hormone stimulates oncogenicity of endometrial carcinoma cells.

Authors:  Vijay Pandey; Jo K Perry; Kumarasamypet M Mohankumar; Xiang-Jun Kong; Shu-Min Liu; Zheng-Sheng Wu; Murray D Mitchell; Tao Zhu; Peter E Lobie
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

4.  The role of LEF1 in endometrial gland formation and carcinogenesis.

Authors:  Dawne N Shelton; Hubert Fornalik; Traci Neff; Soo Yeun Park; David Bender; Koen DeGeest; Xiaoming Liu; Weiliang Xie; David K Meyerholz; John F Engelhardt; Michael J Goodheart
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

5.  Species Comparison of the Role of p38 MAP Kinase in the Female Reproductive System.

Authors:  Zaher A Radi; Rosemary A Marusak; Dale L Morris
Journal:  J Toxicol Pathol       Date:  2009-07-07       Impact factor: 1.628

6.  Enhanced epithelial to mesenchymal transition (EMT) and upregulated MYC in ectopic lesions contribute independently to endometriosis.

Authors:  Katharina Proestling; Peter Birner; Susanne Gamperl; Nadine Nirtl; Erika Marton; Gülen Yerlikaya; Rene Wenzl; Berthold Streubel; Heinrich Husslein
Journal:  Reprod Biol Endocrinol       Date:  2015-07-22       Impact factor: 5.211

Review 7.  New concepts for an old problem: the diagnosis of endometrial hyperplasia.

Authors:  Peter A Sanderson; Hilary O D Critchley; Alistair R W Williams; Mark J Arends; Philippa T K Saunders
Journal:  Hum Reprod Update       Date:  2017-03-01       Impact factor: 15.610

Review 8.  Estrogen Receptor Function: Impact on the Human Endometrium.

Authors:  Kun Yu; Zheng-Yuan Huang; Xue-Ling Xu; Jun Li; Xiang-Wei Fu; Shou-Long Deng
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-28       Impact factor: 5.555

9.  The wedelolactone derivative inhibits estrogen receptor-mediated breast, endometrial, and ovarian cancer cells growth.

Authors:  Defeng Xu; Tzu-Hua Lin; Chiuan-Ren Yeh; Max A Cheng; Lu-Min Chen; Chawnshang Chang; Shuyuan Yeh
Journal:  Biomed Res Int       Date:  2014-08-13       Impact factor: 3.411

10.  Curcumin Inhibits ERK/c-Jun Expressions and Phosphorylation against Endometrial Carcinoma.

Authors:  Zhenxue Zhang; Pengfei Yi; Changchun Tu; Jiejie Zhan; Liping Jiang; Fanglin Zhang
Journal:  Biomed Res Int       Date:  2019-10-31       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.